About Heterogeneous nuclear ribonucleoprotein A1-like 2
Heterogeneous nuclear ribonucleoprotein A1-like 2 (HNRNPA1L2) is a protein
from Homo sapiens identified by UniProt accession
Q32P51, 320 residues long.
MolForge cross-references it against 0 known binders and
136 disease associations.
Target properties
| Protein name | Heterogeneous nuclear ribonucleoprotein A1-like 2 |
| UniProt accession | Q32P51 |
| Gene | HNRNPA1L2 |
| Organism | Homo sapiens |
| Length | 320 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (136)
Diseases linked to this target (Open Targets).
- Red cell distribution width · score 0.10
- familial atrial fibrillation · score 0.09
- Brugada syndrome · score 0.09
- Romano-Ward syndrome · score 0.09
- Arrhythmogenic right ventricular dysplasia · score 0.08
- hypertrophic cardiomyopathy · score 0.08
- Familial short QT syndrome · score 0.08
- Familial progressive cardiac conduction defect · score 0.08
- dilated cardiomyopathy · score 0.07
- familial sick sinus syndrome · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q32P51-F1 | alphafold | PREDICTED | 70.22 | — |
Amino-acid sequence (320 residues)
MSKSASPKEP EQLRKLFIGG LSFETTDESL RSHFEQWGTL TDCVVMRDPN TKRSRGFGFV TYATVEEVDA AMNTTPHKVD GRVVEPKRAV SREDSQRPGA HLTVKKIFVG GIKEDTEEHH LRDYFEQYGK IEVIEIMTDR GSGKKRGFAF VTFDDHDSVD KIVIQKYHTV KGHNCEVRKA LPKQEMASAS SSQRGRRGSG NFGGGRGDGF GGNDNFGRGG NFSGRGGFGG SCGGGGYGGS GDGYNGFGND GSNFGGGGSY NDFGNYNNQS SNFGPMKGGN FGGRSSGPYG GGGQYFAKPQ NQGGYGVSSS SSSYGSGRRF
Explore Heterogeneous nuclear ribonucleoprotein A1-like 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets